$NXEN
Nexien Biopharma Inc

2023 Q4 Form 10-Q Financial Statement

#000149315223041255 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.44K $60.00K $74.32K
YoY Change -81.6% -19.27% -35.34%
% of Gross Profit
Research & Development $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $13.44K $62.00K $74.32K
YoY Change -81.6% -16.58% -35.34%
Operating Profit
YoY Change
Interest Expense -$11.08K -$10.00K -$20.56K
YoY Change -46.11% -51.36% 203.69%
% of Operating Profit
Other Income/Expense, Net -$11.08K -$12.92K -$20.56K
YoY Change -46.1% -37.14% 203.59%
Pretax Income -$24.52K -$70.00K -$94.87K
YoY Change -73.8% -26.21% -22.05%
Income Tax
% Of Pretax Income
Net Earnings -$24.52K -$74.92K -$94.87K
YoY Change -73.8% -21.03% -22.05%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$1.553K
COMMON SHARES
Basic Shares Outstanding 65.27M shares 64.77M shares 61.27M shares
Diluted Shares Outstanding 65.11M shares 64.57M shares 61.07M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.620K $0.00 $101.2K
YoY Change -96.2% -100.0% 2641.19%
Cash & Equivalents $2.619K $18.06K $101.1K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00 $3.810K
YoY Change -100.0% -100.0% 1.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.619K $22.05K $105.0K
YoY Change -96.6% -78.99% 1310.73%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.619K $22.05K $105.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $2.619K $22.05K $105.0K
YoY Change -96.6% -78.99% 1310.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $36.36K $0.00 $25.70K
YoY Change 70.78% -100.0% 184.61%
Accrued Expenses $45.00K $0.00 $45.00K
YoY Change 0.0% -100.0% 125.0%
Deferred Revenue
YoY Change
Short-Term Debt $235.5K $200.0K $194.9K
YoY Change 10.54% 2.63% 959.08%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $316.8K $312.9K $265.6K
YoY Change 13.43% 17.81% 459.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $316.8K $312.9K $265.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $316.8K $312.9K $265.6K
YoY Change 13.43% 17.81% 459.9%
SHAREHOLDERS EQUITY
Retained Earnings -$11.39M -$11.37M -$11.03M
YoY Change 2.45% 3.1%
Common Stock $6.527K $6.477K $6.127K
YoY Change 5.24% 5.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$314.2K -$290.8K -$160.6K
YoY Change
Total Liabilities & Shareholders Equity $2.619K $22.05K $105.0K
YoY Change -96.6% -78.99% 1310.73%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$24.52K -$74.92K -$94.87K
YoY Change -73.8% -21.03% -22.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$12.53K -$17.08K -$15.75K
YoY Change -61.04% 8.46% 9.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -12.53K -$17.08K -$15.75K
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -12.53K -$17.08K -$15.75K
YoY Change -61.04% 8.46%
FREE CASH FLOW
Cash From Operating Activities -$12.53K -$17.08K -$15.75K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001625288
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
000-55320
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
NEXIEN BIOPHARMA, INC.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2049376
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
4340 E Kentucky Ave.
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 206
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Glendale
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80246
CY2023Q3 dei City Area Code
CityAreaCode
(303)
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
495-7583
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65272196 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18064 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35147 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3990 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7980 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
22054 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
43127 usd
CY2023Q3 us-gaap Assets
Assets
22054 usd
CY2023Q2 us-gaap Assets
Assets
43127 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
35961 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23643 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
3561 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
8963 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
312854 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
295134 usd
CY2023Q3 us-gaap Liabilities
Liabilities
312854 usd
CY2023Q2 us-gaap Liabilities
Liabilities
295134 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64772196 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64772196 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64022196 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64022196 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6477 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6402 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11038001 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10986201 usd
CY2023Q3 NXEN Stock Payable
StockPayable
35000 usd
CY2023Q2 NXEN Stock Payable
StockPayable
50750 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11370278 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11295360 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-290800 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-252007 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22054 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43127 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
15540 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
15260 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46455 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59055 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
61995 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
74315 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
7521 usd
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
2421 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5402 usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18138 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12923 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20559 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-74918 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-94874 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.002
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64574394 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64574394 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61074394 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61074394 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-252007 usd
CY2023Q3 NXEN Stock To Be Issued During Period Value Issued For Services
StockToBeIssuedDuringPeriodValueIssuedForServices
35000 usd
CY2023Q3 NXEN Adjustments To Additional Paid In Capital Imputed Interest On Related Party Advances
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyAdvances
1125 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-74918 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-290800 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117605 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117605 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
50750 usd
CY2022Q3 NXEN Adjustments To Additional Paid In Capital Imputed Interest On Related Party Advances
AdjustmentsToAdditionalPaidInCapitalImputedInterestOnRelatedPartyAdvances
1125 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-94874 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-160604 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-160604 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-74918 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-94874 usd
CY2023Q3 NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
1125 usd
CY2022Q3 NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
1125 usd
CY2023Q3 NXEN Stock Issued To Officers
StockIssuedToOfficers
35000 usd
CY2022Q3 NXEN Stock Issued To Officers
StockIssuedToOfficers
50750 usd
CY2023Q3 NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
5402 usd
CY2022Q3 NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
5402 usd
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12736 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3990 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3810 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12318 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5301 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17083 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15750 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17083 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15750 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35147 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
116898 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18064 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
101148 usd
CY2023Q3 us-gaap Stock Issued1
StockIssued1
50750 usd
CY2022Q3 us-gaap Stock Issued1
StockIssued1
50750 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
11370278 usd
CY2023Q3 NXEN Working Capital Deficit
WorkingCapitalDeficit
290800 usd
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zlEt8MzscQH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zMBWrNKObQSk">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023Q3 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022Q3 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2023Q3 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zdy7j9flGFY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zZwjMXNl713c">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2023Q2 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
CY2023 NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y4M9D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2023Q3 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
CY2023Q3 NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y7M6D
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
28274 usd
CY2023Q3 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
14122 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
170454 usd
CY2023Q3 NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
5402 usd
CY2022Q3 NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
5402 usd

Files In Submission

Name View Source Status
0001493152-23-041255-index-headers.html Edgar Link pending
0001493152-23-041255-index.html Edgar Link pending
0001493152-23-041255.txt Edgar Link pending
0001493152-23-041255-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
nxen-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
nxen-20230930_cal.xml Edgar Link unprocessable
nxen-20230930_lab.xml Edgar Link unprocessable
nxen-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nxen-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending